EnteroMedics Releases Clinical Trial Data

EnteroMedics Inc. Thursday announced updated clinical results, including weight loss, HbA1c and hypertension control data, from the company’s VBLOC-DM2 ENABLE, EMPOWER and VBLOC RF2 Studies of VBLOC vagal blocking therapy delivered via the Maestro System.
MarketWatch